FDMT - NASDAQ
4D Molecular Therapeutics, Inc.
$9.53
+2.8%4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
At a Glance
Live Snapshot4D Molecular Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
4D Molecular Therapeutics, Inc. Balance Sheet
FDMT • NASDAQ
| 4D Molecular Therapeutics, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
CURRENT ASSETS | |||||||||
60.2M | 149.3M | 249.1M | 52.4M | 153M | 276.7M | 49.7M | 91.8M | 23.9M | |
342.4M | 275.5M | 39.1M | 161.2M | 94.8M | 0.0 | 0.0 | 0.0 | 0.0 | |
402.7M | 424.9M | 288.2M | 213.6M | 247.8M | 276.7M | 49.7M | 91.8M | 23.9M | |
0.0 | 0.0 | 0.0 | 700K | 47K | 1.5M | 978K | 1.1M | 321K | |
0.0 | 0.0 | 0.0 | 0.0 | 47K | 1.5M | 978K | 1.1M | 321K | |
0.0 | 0.0 | 0.0 | 700K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 8.5M | 0.0 | 1.9M | 783K | 328K | |
10.5M | 10.1M | 8.4M | 6.3M | 0.0 | 4.4M | 0.0 | 0.0 | 0.0 | |
413.1M | 434.9M | 296.6M | 220.5M | 256.3M | 282.7M | 52.5M | 94.1M | 24.5M | |
NON-CURRENT ASSETS | |||||||||
33M | 40.6M | 31.7M | 35.3M | 29M | 5.1M | 5M | 2.5M | 2.7M | |
0.0 | 80.6M | 11M | 4.9M | 67.7M | 0.0 | 0.0 | 0.0 | 0.0 | |
120.6M | 4.3M | 684K | 1.1M | 602K | 602K | 677K | 429K | 105K | |
153.6M | 125.5M | 43.3M | 41.3M | 97.2M | 5.7M | 5.7M | 2.9M | 2.8M | |
566.7M | 560.4M | 339.9M | 261.8M | 353.5M | 288.3M | 58.2M | 97M | 27.3M | |
LIABILITIES | |||||||||
CURRENT LIABILITIES | |||||||||
11.2M | 4.4M | 3.5M | 3.3M | 4.8M | 1.8M | 1.7M | 954K | 460K | |
11.2M | 4.4M | 3.5M | 3.3M | 4.8M | 1.8M | 1.7M | 954K | 460K | |
0.0 | 18.9M | 8.1M | 5.7M | 7.7M | 8.4M | 5.3M | 2.2M | 787K | |
5.6M | 0.0 | 0.0 | 2.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 5.6M | 3.1M | 0.0 | 1.2M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 93K | 51K | |
360K | 257K | 273K | 884K | 2.6M | 6.6M | 5.9M | 4.9M | 4.4M | |
26.9M | 0.0 | 3.9M | 3.2M | 0.0 | 0.0 | 0.0 | 0.0 | 279K | |
44M | 29.1M | 19M | 15.7M | 16.3M | 16.7M | 13M | 8.1M | 5.9M | |
NON-CURRENT LIABILITIES | |||||||||
15.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
745K | 1.1M | 972K | 1.1M | 2.5M | 13.2M | 13.6M | 13.1M | 22.2M | |
496K | 603K | 617K | 233K | 334K | 2M | 104.6M | 103.4M | 18.8M | |
17.1M | 20.6M | 13.1M | 14.8M | 18M | 15.2M | 118.2M | 116.5M | 41M | |
0.0 | 24.6M | 14.7M | 13.5M | 16.4M | 0.0 | 0.0 | 0.0 | 0.0 | |
61M | 49.8M | 32.1M | 30.5M | 34.4M | 31.9M | 131.2M | 124.6M | 46.9M | |
SHAREHOLDERS' EQUITY | |||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 288.3M | 103M | 103M | 18.5M | |
6K | 5K | 4K | 3K | 3K | 3K | 1K | 1K | 1K | |
1.2B | 1.1B | 723.1M | 547M | 526.5M | 392.1M | 6.1M | 2.4M | 884K | |
-716.3M | -576.2M | -415.3M | -314.5M | -207M | -135.7M | -79M | -30M | -20.5M | |
727K | 229K | 16K | -1.2M | -423K | -288.3M | -103M | -103M | -18.5M | |
505.7M | 510.6M | 307.8M | 231.3M | 319.1M | 256.4M | -73M | -27.6M | -19.6M | |
505.7M | 510.6M | 307.8M | 231.3M | 319.1M | 256.4M | -73M | -27.6M | -19.6M | |
SUMMARY | |||||||||
566.7M | 560.4M | 339.9M | 261.8M | 353.5M | 288.3M | 58.2M | 97M | 27.3M | |
342.4M | 356.1M | 50.1M | 166.1M | 162.4M | 0.0 | 0.0 | 0.0 | 0.0 | |
21.4M | 24.6M | 14.7M | 16.1M | 16.4M | 0.0 | 0.0 | 0.0 | 0.0 | |
-38.8M | -124.7M | -234.4M | -36.2M | -136.6M | -276.7M | -49.7M | -91.8M | -23.9M | |
46,702,500 | 46,702,500 | 46,702,500 | 46,702,500 | 46,702,500 | 46,702,500 | 46,702,500 | 46,702,500 | 46,702,500 |
SEC Filings
FDMT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
S-3 S-3 N/A | May 07, 2026 | May 07, 2026 | ||
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 25, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 18, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 18, 2026 | March 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 26, 2026 | January 22, 2026 | 2026 | |
8-K 8-K 2025 N/A | January 07, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 10, 2025 | December 10, 2025 | 2025 |
Related Guides
Continue your FDMT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.